Genetic diversity of simian immunodeficiency virus encoding HIV-1 reverse transcriptase persists in macaques despite antiretroviral therapy

Journal of Virology

Volumn 85, Issue 2, 2011, Pages 1067-1076

  Kearney, Mary ^a   Spindler, Jon ^a   Shao, Wei ^b   Maldarelli, Frank ^a   Palmer, Sarah ^c   Hu, Shiu Lok ^d   Lifson, Jeffrey D ^b   KewalRamani, Vineet N ^a   Mellors, John W ^e   Coffin, John M ^a,f   Ambrose, Zandrea ^e  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c KAROLINSKA INSTITUTE   (Sweden)

^d Washington National Primate Research Center   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^f TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; EMTRICITABINE; RNA DIRECTED DNA POLYMERASE; TENOFOVIR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; GENE SEQUENCE; GENETIC VARIABILITY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MACACA; NONHUMAN; PHYLOGENY; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS; VIREMIA; VIRUS GENOME;

ANIMALS; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CLUSTER ANALYSIS; DISEASE MODELS, ANIMAL; EVOLUTION, MOLECULAR; GENETIC VARIATION; HIV REVERSE TRANSCRIPTASE; MACACA; PHYLOGENY; PLASMA; RECOMBINANT PROTEINS; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VIRAL LOAD;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA; MACACA NEMESTRINA; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 78650637689     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01701-10     Document Type: Article

References (42)

1. Achaz, G., S. Palmer, M. Kearney, F. Maldarelli, J. W. Mellors, J. M. Coffin, and J. Wakeley. 2004. A robust measure of HIV-1 population turnover within chronically infected individuals. Mol. Biol. Evol. 21:1902-1912.
2. Ambrose, Z., V. Boltz, S. Palmer, J. M. Coffin, S. H. Hughes, and V. N. Kewalramani. 2004. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques. J. Virol. 78:13553-13561.
3. Ambrose, Z., S. Palmer, V. F. Boltz, M. Kearney, K. Larsen, P. Polacino, L. Flanary, K. Oswald, M. Piatak, Jr., J. Smedley, W. Shao, N. Bischofberger, F. Maldarelli, J. T. Kimata, J. W. Mellors, S. L. Hu, J. M. Coffin, J. D. Lifson, and V. N. KewalRamani. 2007. Suppression of viremia and evolution of human immunodeficiency virus type 1 drug resistance in a macaque model for antiretroviral therapy. J. Virol. 81:12145-12155.
4. Bailey, J. R., A. R. Sedaghat, T. Kieffer, T. Brennan, P. K. Lee, M. Wind-Rotolo, C. M. Haggerty, A. R. Kamireddi, Y. Liu, J. Lee, D. Persaud, J. E. Gallant, J. Cofrancesco, Jr., T. C. Quinn, C. O. Wilke, S. C. Ray, J. D. Siliciano, R. E. Nettles, and R. F. Siliciano. 2006. Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells. J. Virol. 80:6441-6457.
5. Benito, J. M., M. Lopez, S. Lozano, P. Martinez, J. Gonzalez-Lahoz, and V. Soriano. 2004. CD38 expression on CD8 T lymphocytes as a marker of residual virus replication in chronically HIV-infected patients receiving antiretroviral therapy. AIDS Res. Hum. Retroviruses 20:227-233.
6. Caliendo, A. M., and M. S. Hirsch. 1994. Combination therapy for infection due to human immunodeficiency virus type 1. Clin. Infect. Dis. 18:516-524.
7. Chun, T. W., D. C. Nickle, J. S. Justement, J. H. Meyers, G. Roby, C. W. Hallahan, S. Kottilil, S. Moir, J. M. Mican, J. I. Mullins, D. J. Ward, J. A. Kovacs, P. J. Mannon, and A. S. Fauci. 2008. Persistence of HIV in gutassociated lymphoid tissue despite long-term antiretroviral therapy. J. Infect. Dis. 197:714-720.
8. Coffin, J. M. 1995. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267:483-489.
9. Cohen Stuart, J. W., M. D. Hazebergh, D. Hamann, S. A. Otto, J. C. Borleffs, F. Miedema, C. A. Boucher, and R. J. de Boer. 2000. The dominant source of CD4+ and CD8+ T-cell activation in HIV infection is antigenic stimulation. J. Acquir. Immune Defic. Syndr. 25:203-211.
10. Deere, J. D., J. Higgins, E. Cannavo, A. Villalobos, L. Adamson, E. Fromentin, R. F. Schinazi, P. A. Luciw, and T. W. North. 2010. Viral decay kinetics in the highly active antiretroviral therapy-treated rhesus macaque model of AIDS. PLoS One 5:e11640.
11. Dinoso, J. B., S. Y. Kim, A. M. Wiegand, S. E. Palmer, S. J. Gange, L. Cranmer, A. O'Shea, M. Callender, A. Spivak, T. Brennan, M. F. Kearney, M. A. Proschan, J. M. Mican, C. A. Rehm, J. M. Coffin, J. W. Mellors, R. F. Siliciano, and F. Maldarelli. 2009. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc. Natl. Acad. Sci. U. S. A. 106:9403-9408.
12. Eshleman, S. H., S. E. Hudelson, A. Gupta, R. Bollinger, A. D. Divekar, R. R. Gangakhedkar, S. S. Kulkarni, M. R. Thakar, R. S. Paranjape, and S. Tripathy. 2005. Limited evolution in the HIV type 1 pol region among acute seroconverters in Pune, India. AIDS Res. Hum. Retroviruses 21:93-97.
13. Fitzgibbon, J. E., A. E. Farnham, S. J. Sperber, H. Kim, and D. T. Dubin. 1993. Human immunodeficiency virus type 1 pol gene mutations in an AIDS patient treated with multiple antiretroviral drugs. J. Virol. 67:7271-7275.
14. Gandhi, R. T., L. Zheng, R. J. Bosch, E. S. Chan, D. M. Margolis, S. Read, B. Kallungal, S. Palmer, K. Medvik, M. M. Lederman, N. Alatrakchi, J. M. Jacobson, A. Wiegand, M. Kearney, J. M. Coffin, J. W. Mellors, and J. J. Eron. 2010. The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med. 7:e1000321.
15. Gunthard, H. F., J. K. Wong, C. C. Ignacio, J. C. Guatelli, N. L. Riggs, D. V. Havlir, and D. D. Richman. 1998. Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy. J. Virol. 72:2422-2428.
16. Hammer, S. M., H. A. Kessler, and M. S. Saag. 1994. Issues in combination antiretroviral therapy: a review. J. Acquir. Immune Defic. Syndr. 7(Suppl. 2):S24-S35; discussion, S35-S37.
17. Hatano, H., P. Hunt, J. Weidler, E. Coakley, R. Hoh, T. Liegler, J. N. Martin, and S. G. Deeks. 2006. Rate of viral evolution and risk of losing future drug options in heavily pretreated, HIV-infected patients who continue to receive a stable, partially suppressive treatment regimen. Clin. Infect. Dis. 43:1329-1336.
18. Hudson, R. R., D. D. Boos, and N. L. Kaplan. 1992. A statistical test for detecting geographic subdivision. Mol. Biol. Evol. 9:138-151.
19. Jablonowski, H. 1995. Studies of zidovudine in combination with didanosine and zalcitabine. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 10(Suppl. 1):S52-S56.
20. Jourdain, G., N. Ngo-Giang-Huong, S. Le Coeur, C. Bowonwatanuwong, P. Kantipong, P. Leechanachai, S. Ariyadej, P. Leenasirimakul, S. Hammer, and M. Lallemant. 2004. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N. Engl. J. Med. 351:229-240.
21. Kantor, R., R. W. Shafer, S. Follansbee, J. Taylor, D. Shilane, L. Hurley, D. P. Nguyen, D. Katzenstein, and W. J. Fessel. 2004. Evolution of resistance to drugs in HIV-1-infected patients failing antiretroviral therapy. AIDS 18:1503-1511.
22. Kearney, M., F. Maldarelli, W. Shao, J. B. Margolick, E. S. Daar, J. W. Mellors, V. Rao, J. M. Coffin, and S. Palmer. 2009. Human immunodeficiency virus type 1 population genetics and adaptation in newly infected individuals. J. Virol. 83:2715-2727.
23. Kieffer, T. L., M. M. Finucane, R. E. Nettles, T. C. Quinn, K. W. Broman, S. C. Ray, D. Persaud, and R. F. Siliciano. 2004. Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads. J. Infect. Dis. 189:1452-1465.
24. Kristiansen, T. B., A. G. Pedersen, J. Eugen-Olsen, T. L. Katzenstein, and J. D. Lundgren. 2005. Genetic evolution of HIV in patients remaining on a stable HAART regimen despite insufficient viral suppression. Scand. J. Infect. Dis. 37:890-901.
25. Larder, B. A. 1995. Viral resistance and the selection of antiretroviral combinations. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 10(Suppl. 1): S28-S33.
26. Lee, E. J., R. Kantor, L. Zijenah, W. Sheldon, L. Emel, P. Mateta, E. Johnston, J. Wells, A. K. Shetty, H. Coovadia, Y. Maldonado, S. A. Jones, L. M. Mofenson, C. H. Contag, M. Bassett, and D. A. Katzenstein. 2005. Breast-milk shedding of drug-resistant HIV-1 subtype C in women exposed to single-dose nevirapine. J. Infect. Dis. 192:1260-1264.
27. Maldarelli, F., S. Palmer, M. S. King, A. Wiegand, M. A. Polis, J. Mican, J. A. Kovacs, R. T. Davey, D. Rock-Kress, R. Dewar, S. Liu, J. A. Metcalf, C. Rehm, S. C. Brun, G. J. Hanna, D. J. Kempf, J. M. Coffin, and J. W. Mellors. 2007. ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog. 3:e46.
28. Martinez, E., M. Arnedo, V. Giner, C. Gil, M. Caballero, L. Alos, F. Garcia, C. Holtzer, J. Mallolas, J. M. Miro, T. Pumarola, and J. M. Gatell. 2001. Lymphoid tissue viral burden and duration of viral suppression in plasma. AIDS 15:1477-1482.
29. Martinez, M. A., M. Cabana, A. Ibanez, B. Clotet, A. Arno, and L. Ruiz. 1999. Human immunodeficiency virus type 1 genetic evolution in patients with prolonged suppression of plasma viremia. Virology 256:180-187.
30. Mayers, D. L., A. J. Japour, J. M. Arduino, S. M. Hammer, R. Reichman, K. F. Wagner, R. Chung, J. Lane, C. S. Crumpacker, G. X. cLeod, et al. 1994. Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. The RV43 Study Group. Antimicrob. Agents Chemother. 38:307-314.
31. McMahon, D., J. Jones, A. Wiegand, S. J. Gange, M. Kearney, S. Palmer, S. McNulty, J. A. Metcalf, E. Acosta, C. Rehm, J. M. Coffin, J. W. Mellors, and F. Maldarelli. 2010. Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin. Infect. Dis. 50:912-919.
32. Napravnik, S., D. Edwards, P. Stewart, B. Stalzer, E. Matteson, and J. J. Eron, Jr. 2005. HIV-1 drug resistance evolution among patients on potent combination antiretroviral therapy with detectable viremia. J. Acquir. Immune Defic. Syndr. 40:34-40.
33. Nettles, R. E., T. L. Kieffer, R. P. Simmons, J. Cofrancesco, Jr., R. D. Moore, J. E. Gallant, D. Persaud, and R. F. Siliciano. 2004. Genotypic resistance in HIV-1-infected patients with persistently detectable low-level viremia while receiving highly active antiretroviral therapy. Clin. Infect. Dis. 39:1030-1037.
34. Palmer, S., F. Maldarelli, A. Wiegand, B. Bernstein, G. J. Hanna, S. C. Brun, D. J. Kempf, J. W. Mellors, J. M. Coffin, and M. S. King. 2008. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc. Natl. Acad. Sci. U. S. A. 105:3879-3884.
35. Raboud, J. M., S. Rae, R. Woods, M. Harris, and J. S. Montaner. 2002. Consecutive rebounds in plasma viral load are associated with virological failure at 52 weeks among HIV-infected patients. AIDS 16:1627-1632.
36. Ruiz, L., J. van Lunzen, A. Arno, H. J. Stellbrink, C. Schneider, M. Rull, E. Castella, I. Ojanguren, D. D. Richman, B. Clotet, K. Tenner-Racz, and P. Racz. 1999. Protease inhibitor-containing regimens compared with nucleoside analogues alone in the suppression of persistent HIV-1 replication in lymphoid tissue. AIDS 13:F1-F8.
37. Shafer, R. W., A. K. Iversen, M. A. Winters, E. Aguiniga, D. A. Katzenstein, and T. C. Merigan. 1995. Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. The AIDS Clinical Trials Group 143 Virology Team. J. Infect. Dis. 172:70-78.
38. Shen, L., and R. F. Siliciano. 2008. Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection. J. Allergy Clin. Immunol. 122:22-28.
39. Shiu, C., C. K. Cunningham, T. Greenough, P. Muresan, V. Sanchez-Merino, V. Carey, J. B. Jackson, C. Ziemniak, L. Fox, M. Belzer, S. C. Ray, K. Luzuriaga, and D. Persaud. 2009. Identification of ongoing HIV-1 replication in residual viremia during recombinant HIV-1 poxvirus immunizations in patients with clinically undetectable viral loads on durable suppressive HAART. J. Virol. 83:9731-9742.
40. Siliciano, R. F. 2005. Scientific rationale for antiretroviral therapy in 2005: viral reservoirs and resistance evolution. Top. HIV Med. 13:96-100.
41. Skowron, G. 1992. Treatment of HIV infection: the antiretroviral nucleoside analogues. Nucleoside analogues: monotherapy. Hosp. Pract. (Off. Ed.) 27(Suppl. 2):5-13.
42. Sungkanuparph, S., R. K. Groger, E. T. Overton, V. J. Fraser, and W. G. Powderly. 2006. Persistent low-level viraemia and virological failure in HIV-1-infected patients treated with highly active antiretroviral therapy. HIV Med. 7:437-441.